<DOC>
	<DOCNO>NCT01246986</DOCNO>
	<brief_summary>The purpose study estimate median time progression participant hepatocellular carcinoma ( HCC ) treat LY2157299 monotherapy combination sorafenib ramucirumab .</brief_summary>
	<brief_title>A Study LY2157299 Participants With Hepatocellular Carcinoma</brief_title>
	<detailed_description>The study consist four Parts : Part A HCC participant increase alpha feto protein ( AFP ) level treat either 160 milligram ( mg ) LY2157299 300 mg LY2157299 . Part B HCC participant normal AFP level treat 300 mg LY2157299 , Part C treatment-naïve HCC participant treat 160 mg LY2157299 + sorafenib 300 mg LY2157299 + sorafenib , Part D HCC participant treat either 160 mg 300 mg LY2157299 + ramucirumab . Participants continue receive benefit treatment time study consider complete , may enter treatment extension period continue receive study treatment . The end study date last visit last scheduled procedure last active subject study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Have histological evidence diagnosis HCC amenable curative surgery Part A : Serum alpha fetoprotein great equal 1.5 Upper Limits Normal , Part B : Serum alpha fetoprotein less 1.5 Upper Limits Normal . Not applicable Part C D ChildPugh Stage : A B7 Parts A &amp; B , A Part C , D Have presence measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . A lesion previously treat local therapy qualify measurable evaluable lesion demonstrable progression follow locoregional therapy Have give write informed consent prior studyspecific procedure Have adequate hematologic , hepatic renal function Have performance status equal le 1 Eastern Cooperative Oncology Group ( ECOG ) scale For Parts A &amp; B : Have receive sorafenib progress intolerant sorafenib ineligible sorafenib treatment . For Part C : receive previous systemic treatment . For Part D : receive sorafenib progress intolerant sorafenib ineligible sorafenib treatment receive prior systemic treatment . For Parts A , B , D : discontinue sorafenib least 2 week Are reliable willing make available duration study willing follow study procedure Males female reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug Females childbearing potential must negative serum pregnancy test less equal 7 day prior first dose study drug Are able swallow capsule tablet Are currently enrol , discontinue within last 28 day clinical trial involve investigational drug device approve use drug device ( study drug use study ) , concurrently enrol type medical research judge scientifically medically compatible study Known HCC fibrolamellar mixed histology Presence clinically relevant ascitis History liver transplant require increase immunosuppressive therapy . ( Participants maintenance immunosuppressive therapy liver transplant eligible Part A &amp; B ) Have receive 1 line systemic treatment Parts A , B D Have moderate severe cardiac disease : 1 . Have presence cardiac disease , include myocardial infarction within 6 month prior study entry , unstable angina pectoris , New York Heart Association ( NYHA ) Class III/IV congestive heart failure , uncontrolled hypertension 2 . Have document major electrocardiogram ( ECG ) abnormalities investigator 's discretion 3 . Have major abnormality document echocardiography Doppler 4 . Have predispose condition consistent development aneurysm ascend aorta aortic stress Have serious preexist medical condition , opinion investigator , adequately controlled appropriate therapy would preclude participation study Females pregnant lactate Have history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) unless complete remission therapy disease minimum 3 year . At discretion investigator , hormonerefractory prostate cancer participant stable GnRH agonist therapy breast cancer participant stable antiestrogen therapy may treatment continue Have active infection would interfere study objective influence study compliance For Part C , know hypersensitivity sorafenib excipients For Part D , serious illness medical condition ( ) , include limited following : 1 . The participant undergone major surgery within 28 day prior randomization undergone central venous access device placement within 7 day prior randomization 2 . The participant uncontrolled arterial hypertension ≥150 / ≥90 millimeter mercury ( mm Hg ) despite standard medical management</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>